ESTRELLA IMMUNOPHARMA, INC. Deferred Federal, State and Local, Tax Expense (Benefit)
ESTRELLA IMMUNOPHARMA, INC. (ESLA) reported Deferred Federal, State and Local, Tax Expense (Benefit) of -$22.93 thousand for the 3-month period ending 2023-06-30, per its 10-Q filed 2023-08-01.
Discontinued › Expense Statement › Income Tax
us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit · last filed 2023-08-01
- ESTRELLA IMMUNOPHARMA, INC. deferred federal, state and local, tax expense (benefit) for the quarter ending 2023-06-30 was -$22.93K.
- ESTRELLA IMMUNOPHARMA, INC. deferred federal, state and local, tax expense (benefit) for the quarter ending 2023-03-31 was -$50.38K.
- ESTRELLA IMMUNOPHARMA, INC. deferred federal, state and local, tax expense (benefit) for the quarter ending 2022-12-31 was $494.39K, a 554.62% increase year-over-year.
- ESTRELLA IMMUNOPHARMA, INC. deferred federal, state and local, tax expense (benefit) for the quarter ending 2022-09-30 was -$72.42K.
- ESTRELLA IMMUNOPHARMA, INC. deferred federal, state and local, tax expense (benefit) for fiscal 2022 was $316.80K, a 508.98% increase from fiscal 2021.
- ESTRELLA IMMUNOPHARMA, INC. deferred federal, state and local, tax expense (benefit) for fiscal 2021 was $52.02K.
| Period end | Deferred Federal, State and Local, Tax Expense (Benefit) 2 month | Deferred Federal, State and Local, Tax Expense (Benefit) 3 month | Deferred Federal, State and Local, Tax Expense (Benefit) 3 month as first filed | Deferred Federal, State and Local, Tax Expense (Benefit) 6 month | Deferred Federal, State and Local, Tax Expense (Benefit) 9 month | Deferred Federal, State and Local, Tax Expense (Benefit) 9 month as first filed | Deferred Federal, State and Local, Tax Expense (Benefit) 12 month |
|---|---|---|---|---|---|---|---|
| 2023-06-30 | -$22.93K 10-Q · filed 2023-08-01 | -$73.30K 10-Q · filed 2023-08-01 | $421.09K derived: sum of 3 quarters · filed 2023-08-01 | $348.67K derived: sum of 4 quarters · filed 2023-08-01 | |||
| 2023-03-31 | -$50.38K 10-Q · filed 2023-05-18 | $444.02K derived: sum of 2 quarters · filed 2023-05-18 | $371.60K derived: sum of 3 quarters · filed 2023-05-18 | $296.09K derived: sum of 4 quarters · filed 2023-08-01 | |||
| 2022-12-31 | $494.39K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $421.97K derived: sum of 2 quarters · filed 2023-03-14 | $346.46K derived: sum of 3 quarters · filed 2023-08-01 | $316.80K 10-K · filed 2023-03-14 | |||
| 2022-09-30 | -$72.42K 10-Q · filed 2022-11-14 | -$147.93K derived: sum of 2 quarters · filed 2023-08-01 | -$177.60K 10-Q · filed 2022-11-14 | -$102.07K derived: sum of 4 quarters · filed 2023-08-01 | |||
| 2022-06-30 | -$75.51K 10-Q · filed 2023-08-01 | -$105.18K 10-Q · filed 2023-08-01 | -$29.65K derived: sum of 3 quarters · filed 2023-08-01 | -$52.24K derived: sum of 4 quarters · filed 2023-08-01 | |||
| 2022-03-31 | -$29.66K 10-Q · filed 2023-05-18 | $45.86K derived: sum of 2 quarters · filed 2023-05-18 | $23.28K derived: sum of 3 quarters · filed 2023-05-18 | $22.53K derived: sum of 4 quarters · filed 2023-05-18 | |||
| 2021-12-31 | $75.52K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $52.94K derived: sum of 2 quarters · filed 2023-03-14 | $52.19K derived: sum of 3 quarters · filed 2023-03-14 | $52.02K 10-K · filed 2023-03-14 | |||
| 2021-09-30 | -$22.59K 10-Q · filed 2022-11-14 | $22.59K 10-Q · filed 2021-11-10 | -$23.33K derived: sum of 2 quarters · filed 2022-11-14 | -$23.50K 10-Q · filed 2022-11-14 | $23.50K 10-Q · filed 2021-11-10 | ||
| 2021-06-30 | -$747.00 10-Q · filed 2022-08-08 | -$919.00 10-Q · filed 2022-08-08 | |||||
| 2021-03-31 | -$172.00 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |